Platinum Sponsor

Merck Serono is a biotechnology company engaged in the discovery, manufacturing and marketing of therapeutic products for the treatment of human diseases, with a focus on the reproductive health, neurology, growth, and metabolism markets worldwide. The company, formerly known as Serono S.A., was founded in 1987 and changed its name to Merck Serono S.A. in January 2007. The company is headquartered in Geneva, Switzerland. In January 2009, the company and Apitope entered into a licensing agreement regarding novel peptide therapeutics for the treatment of multiple sclerosis. In February 2009, Merck Serono expanded its collaboration agreement with Ambrx to develop ARX424 multiple sclerosis. In March 2009, Merck Serono and Fast Forward, LLC entered into Collaboration to accelerate development of treatments for multiple sclerosis. In 2009, the company launched Kuvan in Europe, Glucophage Powder, Rebismart the first electronic injection device. In September 2009, the company announced that its product Erbitux has shown increase of survival when administered to 1st-line metastatic colorectal cancer patients.

MERCK SERONO MIDDLE EAST FZ-LLC
Dubai Academic City
Building 3, Ground Floor
PO Box 22730
Dubai, UAE
Tel: +971 4 3752700
Web Site:- www.merckserono.com